Trial Profile
An exploratory clinical study on the safety of combination therapy with effector cell therapy and immune checkpoint inhibitors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Apr 2019
Price :
$35
*
At a glance
- Drugs Immunotherapies (Primary) ; Nivolumab (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions
- 27 Mar 2019 Status changed from active, no longer recruiting to completed.
- 22 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 18 Oct 2017 Status changed from not yet recruiting to recruiting.